

# MANAGEMENT SYSTEM CERTIFICATE

Certificate no.:  
C705684

Initial certification date:  
15 December 2006

Valid:  
15 December 2024 – 14 December 2027

This is to certify that the management system of

## **Suven Pharmaceuticals Limited**

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC,  
Raidurg, Hyderabad - 500081, Telangana, India

and the sites as mentioned in the appendix accompanying this certificate

has been found to conform to the Quality Management System standard:

### **ISO 9001:2015**

This certificate is valid for the following scope:

**Research and manufacture of formulations, bulk actives, drug intermediates and fine chemicals**

Place and date:  
**Barendrecht, 27 August 2024**

For the issuing office:  
**DNV - Business Assurance  
Zwolsseweg 1, 2994 LB Barendrecht,  
Netherlands**



**Erie Koek**  
Management Representative

## Appendix to Certificate

### Suven Pharmaceuticals Limited

Locations included in the certification are as follows:

Site Name	Site Address	Site Scope
Suven Pharmaceuticals Limited	Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIIC, Raidurg, Hyderabad - 500081, Telangana, India	Top management, marketing, purchase and HR Activities
Suven Pharmaceuticals Limited	Suryapet Unit: Dasaigudem, Suryapet (M), Suryapet (Dist.) - 508213, Telangana, India	In process development, manufacturing of drug intermediates and fine chemicals
Suven Pharmaceuticals Limited	Plot Nos. 65 to 67, JN Pharma city, Thanam (V), Parawada (M), Visakhapatnam - 531019, Andhra Pradesh, India	In process development, manufacturing of drug intermediates and fine chemicals
Suven Pharmaceuticals Limited	Jeedimetla Unit: Plot No-18, Phase - III,IDA,Jeedimetla,Hyderabad - 500 055, Telangana, India	Research and manufacturing of drug intermediates and fine chemicals
Suven Pharmaceuticals Limited	Pashamylaram Unit :, Plot.No.262 to 271, IDA, Pashamylaram, Pashamylaram - 502 307, Telangana, India	In process development, manufacturing of bulk actives, drug intermediates and formulation